S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843296.73803.85 |
| _version_ | 1797285847347757056 |
|---|---|
| author | H. Erba P. Montesinos R. Vrhovac E. Patkowska H.-J. Kim P. Zak P.-N. Wang T. Mitov J. Hanyok L. Liu A. Benzohra A. Lesegretain J. Cortes A. Perl M. Sekeres H. Dombret S. Amadori J. Wang M. Levis R. Schlenk |
| author_facet | H. Erba P. Montesinos R. Vrhovac E. Patkowska H.-J. Kim P. Zak P.-N. Wang T. Mitov J. Hanyok L. Liu A. Benzohra A. Lesegretain J. Cortes A. Perl M. Sekeres H. Dombret S. Amadori J. Wang M. Levis R. Schlenk |
| author_sort | H. Erba |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:12Z |
| format | Article |
| id | doaj.art-14cfe89f08fe40e09ed1e992c0372c53 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:12Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-14cfe89f08fe40e09ed1e992c0372c532024-03-02T07:47:34ZengWileyHemaSphere2572-92412022-06-0161210.1097/01.HS9.0000843296.73803.85202206003-00001S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AMLH. Erba0P. Montesinos1R. Vrhovac2E. Patkowska3H.-J. Kim4P. Zak5P.-N. Wang6T. Mitov7J. Hanyok8L. Liu9A. Benzohra10A. Lesegretain11J. Cortes12A. Perl13M. Sekeres14H. Dombret15S. Amadori16J. Wang17M. Levis18R. Schlenk191 Duke Cancer Institute, Durham, NC, United States of America2 La Fe University and Polytechnic Hospital, Valencia, Spain3 University Hospital Centre Zagreb, Zagreb, Croatia4 Institute of Hematology and Blood Transfusion, Warsaw, Poland5 The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea6 University Hospital Hradec Kralove, Hradec Kralove, Czechia7 Chang Gung Medical Foundation, Linkou, Taiwan8 Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom9 Daiichi Sankyo, Inc, Basking Ridge, NJ9 Daiichi Sankyo, Inc, Basking Ridge, NJ9 Daiichi Sankyo, Inc, Basking Ridge, NJ9 Daiichi Sankyo, Inc, Basking Ridge, NJ10 Augusta University Medical Center, Augusta, GA11 University of Pennsylvania, Philadelphia, PA12 University of Miami Health System, Miami, FL, United States of America13 Saint Louis Hospital, University of Paris, Paris, France14 Tor Vergata Polyclinic Hospital Rome, Rome, Italy15 Institute of Hematology and Blood Diseases Hospital, Tianjin, China16 Johns Hopkins University, Baltimore, MD, United States of America17 Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000843296.73803.85 |
| spellingShingle | H. Erba P. Montesinos R. Vrhovac E. Patkowska H.-J. Kim P. Zak P.-N. Wang T. Mitov J. Hanyok L. Liu A. Benzohra A. Lesegretain J. Cortes A. Perl M. Sekeres H. Dombret S. Amadori J. Wang M. Levis R. Schlenk S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML HemaSphere |
| title | S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML |
| title_full | S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML |
| title_fullStr | S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML |
| title_full_unstemmed | S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML |
| title_short | S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML |
| title_sort | s100 quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single agent continuation in patients aged 18 75 years with newly diagnosed flt3 itd aml |
| url | http://journals.lww.com/10.1097/01.HS9.0000843296.73803.85 |
| work_keys_str_mv | AT herba s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT pmontesinos s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT rvrhovac s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT epatkowska s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT hjkim s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT pzak s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT pnwang s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT tmitov s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT jhanyok s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT lliu s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT abenzohra s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT alesegretain s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT jcortes s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT aperl s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT msekeres s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT hdombret s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT samadori s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT jwang s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT mlevis s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml AT rschlenk s100quizartinibprolongedsurvivalvsplaceboplusintensiveinductionandconsolidationtherapyfollowedbysingleagentcontinuationinpatientsaged1875yearswithnewlydiagnosedflt3itdaml |